Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are Revuforj, a menin inhibitor, which has completed phase 2 clinical trial for the treatment of relapsed or refractory and acute leukemia. The company is revumenib for R/R mNPM1 AML and studying the use of revumenib in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia across the treatment landscape, including in newly diagnosed patients. It also developing  Niktimvo, a colony stimulating factor-1 receptor, blocking antibody, which is in phase 2 clinical trial for the treatment of chronic graft-versus-host disease. The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Syndax Pharmaceuticals Inc.

In a report released today, from Mizuho Securities maintained a Buy rating on Syndax Pharmaceuticals, with a price target of $45.00. In a report re...

Mizuho Securities Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)

In a report released today, Jason Zemansky from Bank of America Securities reiterated a Buy rating on Syndax Pharmaceuticals, with a price target o...

Bank of America Securities Sticks to Its Buy Rating for Syndax Pharmaceuticals (SNDX)

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Syndax Pharmaceuticals, with a price target of $44.00. T...

Stifel Nicolaus Remains a Buy on Syndax Pharmaceuticals (SNDX)

Barclays analyst Peter Lawson maintained a Buy rating on Syndax Pharmaceuticals today and set a price target of $19.00. The company’s shares closed...

Barclays Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)

The latest update is out from Syndax Pharmaceuticals ( ($SNDX) ). On October 24, 2025, Syndax Pharmaceuticals announced that the FDA approved Revuf...

Market Cap	$1.27B	P/E Ratio	N/A
52W High	$18.00	52W Low	$8.58
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-113.6%	52W Position	94.1%
Overall Score	60	Value Score	40
Quality Score	--	Technical Score	81

EPS Current Est	$-3.18	EPS Next Est	$-1.43
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SNDX	$17.44	+2.29%	1.87M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SNDX	$17.44	+2.3%	1.87M
3
4
5
6

SNDX

SNDX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Syndax Pharmaceuticals Inc. Data in Excel

Get Syndax Pharmaceuticals Inc. Data in Excel